



Figure S1. Changes in the viability of human glioma cells under the action of temozolomide followed by the addition of VV-GMCSF-Lact. VV-GMCSF-Lact was added to the cells after 24 h incubation with TMZ. CD50(VV)—multiplicity of virus infection, in which 50% of cells die; VV—VV-GMCSF-Lact; TMZ—temozolomide.